Asciminib: an investigational agent for the treatment of chronic myeloid leukemia

References

• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927.
   PubMed Web of Science ®Google Scholar
• Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.
   PubMed Web of Science ®Google Scholar
• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–2857.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–984.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv41–iv51.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–2340.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–1054.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–237.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48–56.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia. Leukemia. 2016;30:1648–1671.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Breccia M, Saglio G, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495–1502.
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2094 CML patients from the EUTOS population-based registry. Leukemia. 2017;31:593–601.
   PubMed Web of Science ®Google Scholar
• Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of BCR-ABL dependent cell proliferation. Nat Chem Biol. 2006;2:95–102.
   PubMed Web of Science ®Google Scholar
• Jahnke W, Grotzfeld RM, Pellè X, et al. Binding or bending: distinction of allosteric ABL kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc. 2010;132:7043–7048.
   PubMed Web of Science ®Google Scholar
• Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–737.
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120–8135.
   PubMed Web of Science ®Google Scholar
• Manely PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–2326.
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Kim DW, Cortes J, et al. Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. EHA 2019; S884
   Google Scholar
• Cortes J, Lang F, Kim DW, et al. Combination therapy using asciminib plus imatinib (ima) in patients with chronic myeloid leukemia (CML): results from a phase 1 study. EHA 2019; S883
   Google Scholar
• Cortes J, Hughes TP, Mauro MJ, et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial. Blood. 2020;136(s1):47–50.
   Google Scholar
• Hughes T, Mauro MJ, Kim D, et al. Asciminib in heavily pretreated patients with Ph+CML-CP sensitive to TKI therapy. EHA 2020: S170
   Google Scholar
• Hochhaus A, Boquimpani C, Rea D, et al. Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with > 2 tyrosine kinase inhibitors. Blood. 2020;136(s1):LBA–4.
   Google Scholar
• Qiang W, Antelope O, Zabriskie MS, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31:2844–2847.
   PubMed Web of Science ®Google Scholar
• Eadie LN, Saunders VA, Branford S, et al. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget. 2018;9:13423–13437.
   PubMedGoogle Scholar
• ClinicalTrials.gov. Frontline asciminib combination in chronic phase CML (CMLXI). CML (CMLXI). cited 2021 Jan 21. Available from: https://clinicaltrials.gov/ct2/show/NCT03906292
   Google Scholar
• ClinicalTrials.gov. ABL001 for the treatment of chronic myeloid leukemia in patients who are on therapy with tyrosine kinase inhibitor. cited 2021 Jan 21. Available from: https://clinicaltrials.gov/ct2/show/NCT04216563
   Google Scholar
• ClinicalTrials.gov. Asciminib in monotherapy for chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML). cited 2021 Jan 21. Available from: https://clinicaltrials.gov/ct2/show/NCT04666259
   Google Scholar
• ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). cited 2021 Jan 21. Available from: https://clinicaltrials.gov/ct2/show/NCT03578367
   Google Scholar
• ClinicalTrials.gov. Pharmacokinetics study of asciminib in subjects with impaired renal function compared to matched healthy volunteers. cited 2021 Jan 21. Available from: https://clinicaltrials.gov/ct2/show/NCT03605277
   Google Scholar
• ClinicalTrials.gov. A trial to evaluate the pharmacokinetics of ABL001 in healthy and hepatic impaired subjects. cited 2021 Jan 21. Available from: https://clinicaltrials.gov/ct2/show/NCT02857868
   Google Scholar
• Garcia-Gutierrez V, Luna A, Alonso-Dominguez JM, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021;11(2):16.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415–423.
   PubMed Web of Science ®Google Scholar
• Breccia M, Olimpieri PP, Olimpieri O, et al. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian medicines agency (AIFA). Cancer Med. 2020;9:4160–4165.
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431–443.
   PubMed Web of Science ®Google Scholar